$ESPR

Fischer Seth H. Z. sold (to issuer) 141,023 shares of ESPR

Fischer Seth H. Z. sold (to issuer) 141,023 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.

Original reporting
SEC EDGAR · Fischer Seth H. Z.
Published Jul 13, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 13, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ESPR
Neutral
medium confidence
Mentioned
$ESPR
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ESPRNeutralLow
01

Why it matters

The newest concrete fact is the director’s sale of 141,023 shares to the issuer on 2026-07-13; no price/value or 10b5-1 plan details are provided.

02

Market read

Traders may note insider selling, but the lack of disclosed price/value and absence of other catalysts makes this low-signal for valuation.

03

What to watch

Because the price and total value are not disclosed, the economic magnitude and intent are hard to infer; check for related Form 4s around the same date.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-13, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc.

Company-level read

Ticker impact

$ESPRNeutralMedium confidence
Context

Esperion Therapeutics director Fischer Seth H. Z. sold 141,023 shares to the issuer on 2026-07-13, with price undisclosed.

Expected impact

Likely minimal, unless follow-on filings show unusual scale or repeated selling.

Evidence & confidence

Form 4 shows a director role and a sale to issuer, but the filing provides no transaction price/value and no accompanying corporate event or guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

A sale to the issuer can be administrative or part of a structured program, so it may not reflect bearish expectations.

Key entities

  • Esperion Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ESPR).

  • Fischer Seth H. Z.

    Director who sold 141,023 shares to the issuer on 2026-07-13.

Related articles